In this week’s issue of Nature, an international research team describes how structural signatures can be used to distinguish between the effects of mutation and selection in cancer genomes. Graham Bignell of the Wellcome Trust Sanger Institute and his colleagues identified 2,428 somatic homozygous deletions in 746 cancer cell lines.